Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Retained Earnings (2022 - 2025)

TriSalus Life Sciences' Retained Earnings history spans 4 years, with the latest figure at -$330.6 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 18.26% year-over-year to -$330.6 million; the TTM value through Dec 2025 reached -$330.6 million, down 18.26%, while the annual FY2025 figure was -$330.6 million, 18.26% down from the prior year.
  • Retained Earnings reached -$330.6 million in Q4 2025 per TLSIW's latest filing, down from -$321.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$11.5 million in Q2 2022 to a low of -$330.6 million in Q4 2025.
  • Average Retained Earnings over 4 years is -$189.4 million, with a median of -$255.6 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: increased 0.19% in 2023, then plummeted 1788.1% in 2024.
  • A 4-year view of Retained Earnings shows it stood at -$186.4 million in 2022, then crashed by 33.88% to -$249.5 million in 2023, then decreased by 12.04% to -$279.5 million in 2024, then decreased by 18.26% to -$330.6 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Retained Earnings are -$330.6 million (Q4 2025), -$321.0 million (Q3 2025), and -$298.2 million (Q2 2025).